Design Therapeutics, Inc.
DSGNDesign Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of small-molecule gene targeted chimera (GeneTAC) molecules.
Earnings
Next report
Aug 6, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Design Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of small-molecule gene targeted chimera (GeneTAC) molecules. The company's platform is designed to modify the underlying cause of inherited nucleotide repeat expansion diseases by selectively modulating gene expression. Their approach aims to restore cellular health in degenerative, monogenic conditions where protein production is either insufficient or toxic.
Design Therapeutics is a pioneer in the GeneTAC platform, offering a small-molecule alternative to complex biologics like gene therapy and gene editing.
Questions, answered.
- What is Design Therapeutics, Inc.'s market cap?
- Design Therapeutics, Inc. (DSGN) has a market capitalization of $742.0M and trades on NASDAQ.
- Who are Design Therapeutics, Inc.'s competitors?
- Design Therapeutics, Inc.'s key competitors include Lexeo Therapeutics, Avidity Biosciences, Larimar Therapeutics, and others. These companies compete in similar markets and product categories.
- Who does Design Therapeutics, Inc. partner with?
- Design Therapeutics, Inc.'s notable partners include Wisconsin Alumni Research Foundation, Biogen, Novartis, and others.
- Where is Design Therapeutics, Inc. headquartered?
- Design Therapeutics, Inc. is headquartered in United States of America and employs approximately 57 people. It has been publicly traded since 2021.